In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2406-2417

  Rawat, Manoj K ^a   Jain, Achint ^a   Singh, Sanjay ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Bioavailability; Crystal defects; Cytotoxicity; First pass metabolism; Lipid; Lipid safety profile; Lymphatic transport; PK PD correlation; Repaglinide; Solid lipid nanoparticles

Indexed keywords

GLYCEROL STEARATE; PHOSPHATIDYLCHOLINE; POLOXAMER; REPAGLINIDE; SOLID LIPID NANOPARTICLE; TRISTEARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ZETA POTENTIAL;

EID: 79954506006     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22454     Document Type: Article

References (44)

1. Fahr A, Liu X. 2007. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 4:403-416.
2. Muller RH, Mehnert W, Lucks JS, Schwarz C, Muhlen AZ, Weyhers H, Freitas C, Ruhl D. 1995. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 41:62-69.
3. Muller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of art. Eur J Pharm Biopharm 50:161-177.
4. Muhlen AZ, Schwarz C, Mehnert W. 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 45:149-155.
5. Porter CJ, Charman WN. 2001. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev 50:S127-S147.
6. Cai Z, Wang Y, Zhu LJ, Liu ZQ. 2010. Nanocarriers: A general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab 11:197-207.
7. Yang S, Zhu J, Lu Y, Liang B, Yang C. 1999. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16:751-757.
8. Varshosaz J, Tabbakhian M, Mohammadi MY. 2009. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res 3:1-11.
9. Hu L, Jia H, Luo Z, Liu C, Xing Q. 2010. Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles. Pharmazie 65:110-113.
10. Liu CH, Wu CT, Fang JY. 2010. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery. Drug Dev Ind Pharm 6:1-11.
11. Manjunath K, Reddy JS, Venkateswarlu V. 2005. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 27:127-144.
12. Mehnert W, Mader K. 2001. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 47:165-196.
13. Mayer-Davis EJ, Levin S, Bergman RN. 2001. Insulin secretion, obesity, and potential behavioral influences: Results from the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Metab Res 17:137-145.
14. Muller RH, Massen S, Schwarz C, Mehnert W. 1997. Solid lipid nanoparticles (SLN) as potential carrier for human use: Interaction with human granulocytes. J Control Rel 47:261-269.
15. Scholer N, Zimmermann E, Katzfey U, Hahn H, Muller RH, Liesenfeld O. 2000. Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages. J Microencapsul 17:639-650.
16. Scholer N, Hahn H, Muller RH, Liesenfeld O. 2002. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 14:167-176.
17. Muthu MS, Singh S. 2008. Studies on biodegradable polymeric nanoparticles of risperidone: In vitro and in vivo evaluation. Nanomedicine 2:233-240.
18. Verger ML, Fluckiger L, Kim Y. 1998. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 46:137-143.
19. Holm R, Mullertz A, Christensen E, Hoy CE. 2001. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur J Pharm Sci 14:331-337.
20. Singh S, Muthu MS. 2007. Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. Nanomedicine 3:305-319.
21. Moneghini M, Volinovich D, Princivalle F. 2000. Formulation and evaluation of vinypyrrolidone/vinylacetate copolymer microspheres with carbamazepine. Pharm Dev Technol 5:347-353.
22. Kim A, Yun MO, Oh YK, Ahn WS, Kim CK. 1999. Pharmacodynamic of insulin in polyethylene glycol-coated liposomes. Int J Pharm 180:75-81.
23. Lu Y, Zhang Y, Yang Z, Tang X. 2009. Formulation of an intravenous emulsion loaded with clarithromycin-phospholipid complex and its pharmacokinetics in rats. Int J Pharm 366:160-169.
24. Ruzilawati AB, Wahab MSA, Imran A, Ismail Z, Gana SH. 2007. Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. J Pharm Biomed Anal 43:1831-1831.
25. Goldberg IJ, Isaacsa A, Sehayekb E, Breslowb JL, Huanga LS. 2004. Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice. Atherosclerosis 172:47-53.
26. Adikwu MU, Yoshikawa Y, Takada K. 2004. Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. Biomaterials 25:3041-3048.
27. Yassad A, Lavoinne A, Bion A, Daveau M, Husson A. 1997. Glutamine accelerates interleukin-6 production by rat peritoneal macrophages in culture. FEBS Lett 413:81-84.
28. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
29. Grando FC, Felicio CA, Twardowschy A, Paula FM, Batista VG, Fernandes LC, Curi R, Nishiyama A. 2009. Modulation of peritoneal macrophage activity by the saturation state of the fatty acid moiety of phosphatidylcholine. Braz J Med Biol Res 42:599-605.
30. Quintanar GD, Allemann E, Doelker E, Fessi H. 1997. A mechanistic study of the formation of polymer nanoparticles by the emulsification-diffusion technique. Colloid Polymer Sci 275:640-647.
31. Schubert MA, Muller-Goymann CC. 2003. Solvent injection as a new approach for manufacturing lipid nanoparticles. Evaluation of the method and process parameters. Eur J Pharm Biopharm 55:125-131.
32. Betancourt T, Brown B, Brannon-Peppas L. 2007. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: Preparation, characterization and in vitro evaluation. Nanomedicine 2:219-232.
33. Jenning V, Thunemann AF, Gohla SH. 2000. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199:167-177.
34. Bunjes H, Westesen K, Koch MHJ. 1996. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 129:159-173.
35. Jenning V, Gohla SH. 2001. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul 18:149-158.
36. Westesen K, Bunjes H, Koch MHJ. 1997. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 48:223-236.
37. Reddy H, Murthy RSR. 2005. Etoposide-loaded nanoparticles made from glyceride lipids: Formulation, characterization, in vitro drug release, and stability evaluation. AAPS PharmSciTech 6:E158-E166.
38. Hu FQ, Jiang SP, Du YZ. 2005. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 45:167-173.
39. Mansbach CM, Nevin P. 1998. Intracellular movement of triacylglycerols in intestine. J Lipid Res 39:963-968.
40. Cavalli R, Bargoni A, Podio V, Muntoni E. 2003. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 92:1085-1094.
41. Ros E. 2000. Intestinal absorption of triglyceride and cholesterol, dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 151:357-379.
42. Nordskog BK, Phan CT, Nutting DF, Tso P. 2001. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv Drug Deliv Rev 50:21-44.
43. Holm R, Mullertz A, Pedersen GP, Christensen HG. 2001. Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids. Pharm Res 18:1299-1304.
44. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB. 2006. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 317:82-89.